Design of a randomized, placebo-controlled, Phase 3 trial of tofersen initiated in clinically presymptomatic SOD1 variant carriers: The ATLAS study

Authors

Michael Benatar, University of Miami
Robert C Bucelli, Washington University School of Medicine in St. Louis
et al.

Journal

Neurotherapeutics

Publication Date

7-1-2022

Volume

19

Issue

4

First Page

1248

Last Page

1258

Document Type

Open Access Publication

DOI

10.1007/s13311-022-01237-4

Rights and Permissions

Benatar, M., Wuu, J., Andersen, P.M. et al. Design of a Randomized, Placebo-Controlled, Phase 3 Trial of Tofersen Initiated in Clinically Presymptomatic SOD1 Variant Carriers: the ATLAS Study. Neurotherapeutics 19, 1248–1258 (2022). https://doi.org/10.1007/s13311-022-01237-4 This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Recommended Citation

Benatar, Michael; Bucelli, Robert C; and et al., "Design of a randomized, placebo-controlled, Phase 3 trial of tofersen initiated in clinically presymptomatic SOD1 variant carriers: The ATLAS study." Neurotherapeutics. 19, 4. 1248 - 1258. (2022).
https://digitalcommons.wustl.edu/oa_4/454